CD274 and neoplasm: For immunotherapy, researchers have focused on several biomarkers, mainly PD-L1 [32–35], the tumor mutation burden (TMB) [36–38], Mismatch repair (MMR) status [39], and tumor-infiltrating lymphocytes (TILs) [40–42].